Clinical Trials

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05256225 2026-04-22

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT06423326 2026-04-22

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

36 enrolled

Pancreatic Neoplasms

NCT07061977 2026-04-22

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT05564377 2026-04-21

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06058377 2026-04-21

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06096844 2026-04-21

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

304 enrolled

Lung Neoplasms

NCT06203600 2026-04-21

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Phase 2/3 Recruiting

224 enrolled

Adenocarcinoma Of Esophagus

NCT07198074 2026-04-21

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

255 enrolled

Endometrial Neoplasms

NCT06561685 2026-04-20

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

340 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT03606967 2026-04-17

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Triple Negative Breast Neoplasms

NCT04158635 2026-04-17

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

21 enrolled

Pancreatic Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT04615013 2026-04-16

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

GastrointestinalGynecologic

24 enrolled

Cervical Esophagus Adenocarcinoma

NCT05039801 2026-04-15

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

DermatologicGynecologicHead & NeckSarcoma

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

681 enrolled

Neoplasm Metastasis, Neoplasms

NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

240 enrolled

Neoplasm Metastasis

NCT03907475 2026-04-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

115 enrolled

Neoplasm Metastasis

NCT05019716 2026-04-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

36 enrolled

Advanced NUT Carcinoma

NCT05422794 2026-04-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

57 enrolled

Triple Negative Breast Neoplasms

NCT05673200 2026-04-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

32 enrolled

Triple Negative Breast Neoplasms

NCT05685602 2026-04-13

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

43 enrolled

Pancreatic Neoplasms

NCT07195734 2026-04-13

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

180 enrolled

Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07281417 2026-04-13

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

108 enrolled

Sinonasal Squamous Cell Carcinoma

NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

38 enrolled

Pancreatic Adenocarcinoma

NCT05753306 2026-04-08

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

GastrointestinalOther neoplasm

40 enrolled

Gastric Adenocarcinoma

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Lung Neoplasms

NCT06483555 2026-04-01

PANGEA

DermatologicGastrointestinal

104 enrolled

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT06904378 2026-03-30

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

61 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT06323460 2026-03-24

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT04253964 2026-03-19

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05285358 2026-03-13

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

12 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT07320586 2026-03-13

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

40 enrolled

Stomach Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

28 enrolled

Triple Negative Breast Neoplasms

NCT07049055 2026-02-27

Carolyn-USA

144 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms, Disease Progression

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

51 enrolled

Lung Neoplasms

NCT04115163 2026-02-11

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

67 enrolled

Phase EARLY_PHASE1 Recruiting

Pancreatic Neoplasms

NCT05415709 2026-02-11

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

45 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

68 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT07340398 2026-01-21

TAYLOR

200 enrolled

HER2-positive Early Breast Cancer

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

BreastGastrointestinalGenitourinaryGynecologic

43 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT06320405 2025-12-29

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

38 enrolled

Neoplasm Metastasis

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

43 enrolled

Pancreatic Neoplasms

NCT04858009 2025-12-16

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

40 enrolled

Pancreatic Neoplasms

NCT06385925 2025-12-15

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

440 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06783140 2025-12-05

PLATINUM-CAN

Phase 2/3 Recruiting

10 enrolled